The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025)